Major bleeding is common after primary PCI for STEMI and associated with increased mortality during 1 year follow-up. The CRUSADE bleeding risk score underestimated the risk of major bleeding and therefore the use of this tool might be limited in STEMI. Georgtown University, Washington, DC Background: Red cell distribution width (RDW), a numerical measure of the variability of the size of circulating erythrocytes, has been shown to be an independent predictor of mortality in cardiovascular disease, and in patients undergoing PCI. The purpose of this study was to determine if RDW is a prognostic marker of major post-PCI bleeding. Methods: The study population included 4387 patients with coronary artery disease who were subjected to PCI. The RDW was derived from a complete blood count (CBC) drawn before PCI. Major bleeding was defined as hematocrit decrease Ն15%, transfusion of Ն2 units of packed red blood cells, gastrointestinal or intracerebral bleeding. Multivariable logistic analysis of major in-hospital bleeding was performed using a logistic regression model. Baseline characteristics associated with bleeding were included in the model. Results: In 250 patients with a bleed, RDW was significantly higher than in the 4137 patients who did not bleed (14.4 ϩ/Ϫ 2.1% vs 13.5 ϩ/Ϫ 1.6%, p Ͻ0.001). On multivariable analysis, after adjustment for known correlates of bleeding, RDW was a significant predictor of bleeding (OR 1.14, 95% CI 1.05-1.23, pϭ0.002). (Table 1 ) Conclusions: RDW, an easily obtainable marker, has a strong independent linear relationship with major post-procedure bleeding in patients undergoing PCI. These data suggest that further investigation is necessary to determine the relationship of RDW and bleeding post-PCI.
Georgtown University, Washington, DC Background: Consensus guidelines recommend discontinuation of thienopyridine therapy 5-7 days before planned coronary artery bypass graft (CABG) surgery to reduce bleeding-related events. However, surgery is often performed within this time period to reduce the risk of ischemic events. Evidence supporting the use of on-treatment platelet reactivity testing before CABG is limited. Methods: Patients undergoing CABG within 5 days of thienopyridine discontinuation were prospectively enrolled from 08/2010 to 02/2012. On-treatment platelet reactivity was measured with Verify Now (VN) P2Y12 assay, vasodilator stimulated phosphoprotein phosphorylation (VASP) and light transmittance aggregometry (LTA) with 5 and 20 M of ADP. The primary end point was in-hospital major bleeding (IHMB), defined as bleeding intracranially, that associated with hemodynamic compromise, a hemoglobin drop of Ͼ5 g/dl, or a hematocrit drop of Ͼ15%. The relation between platelet reactivity value and IHMB was assessed with Wilcoxon rank-sum test; its relation with hematocrit (Htc) drop was evaluated with Spearman correlation. Results: The population consisted of 80 patients. IHMB occurred in 37 patients (46.3%). VASP and LTA with 5 M or 20 M of ADP were associated with the primary endpoint (IHMB). (Table) VN and VASP levels demonstrated an inverse correlation with the degree of Htc drop after CABG (pϭ0.002 and 0.041, respectively). A VASP platelet reactivity index (PRI) of 50% is predictive of IHMB (pϭ0.013), but a cut-off value of 230 P2Y12 reaction units (PRU) for VN is not (pϭ0.26). Surgical related bleeding is not predicted by platelet reactivity testing. Conclusions: On-treatment platelet reactivity testing with VASP or LTA 5 M or 20 M of ADP before CABG are able to predict the occurrence IHMB. A VASP PRI value of Ͻ50% may indicate the need to postpone surgery for patients undergoing CABG within 5 days of thienopyridine discontinuation.
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